ClinicalTrials.gov - Search for ongoing and completed clinical trials involving neuropeptides, Cerebrolysin, and novel brain-targeting peptide therapies
Key benefits include: For agar-based nanoparticles, Angiopep-2 provides a robust and well-validated targeting option, particularly for neurological disease applications
When I talked to her last autumn, she scored 6
Iran War Berlin Pride Attack World Politics Entertainment HealthWatch MoneyWatch Crime Space Sports Brand Studio The Free Press Local News Atlanta Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News 24/7 Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas 48 Hours 60 Minutes Shows 48 Hours 60 Minutes CBS Evening News CBS Mornings CBS Morning News CBS Reports CBS Saturday Morning The Daily Report The Dish Face the Nation Sunday Morning The Takeout Things That Matter The Uplift CBS News Investigates CBS News Confirmed Podcasts Newsletters Download Our App CBS News Team Executive Team Brand Studio Paramount+ Join Our Talent Community RSS Feeds Boston | News Weather Sports Video WBZ Features All News Health I-Team Politics Education Business Consumer Entertainment NEXT Weather Forecast Radar & Maps School Closings School Visits Earth Matters Share Photos and Videos Join Weather Watchers All Sports CBS Sports HQ Patriots Red Sox Celtics Bruins Revolution Odds New England Living Question Everything It Happens Here Keller @ Large Wednesday's Child Climate Watch Change Makers Contact Us TV Schedule Meet Our Team Station Info Contests Jobs & Internships Download Our App Obituaries Watch CBS News Drug maker Eli Lilly says GLP-1 pill shows large success in clinical trial Eli Lilly, which makes Zepbound and Mounjaro, reports that in a phase one clinical trial, a once daily GLP-1 pill helped lower the hemoglobin A1C, a measure of blood sugar control, in people with type 2 diabetes
Historically, no, but qualifying Medicare beneficiaries can get coverage for Wegovy from July 1, 2026, until December 31, 2027, via the new Medicare GLP-1 Bridge program
